Sign in Create account

Gufic Biosciences Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: GUFICBIO BSE: 509079
₹432.00
▼ -4.50 (-1.03%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
53/100
Moderate
Valuation
8/100
Expensive
Momentum
51/100
Neutral

QVM read Mixed signals Quality Moderate, Valuation Expensive, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹4,332 Cr
PE (TTM)
58.9
Industry median 36.1 (152 companies)
Price to Book
6.5
PEG (TTM)
2.9
Institutions holding %
4.14%
FII + DII, latest filed period
Piotroski Score
4
Relative return vs Nifty50, qtr %
16.3
Relative return vs Sector, qtr %
9.5
Free Cash Flow
₹14 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
86.67%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
3.27%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
15.46%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
158.01%
as of March 31, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
14.94%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.55
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.58
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
3.71
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
8.16%
as of March 31, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
15.14%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
13.96%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
4.78%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
14.94%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
9.66%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 7 met
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 4)
  • No Debt to equity is below 0.5 (0.58)
  • No Return on equity is 15% or more (9.7%)
  • Yes Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

3 of 3 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

3 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

1 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Sell Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-1.0%
Low 429.0000 · High 452.0000
1W return
-1.2%
Low 413.6000 · High 452.0000
1M return
3.8%
Low 404.1000 · High 467.8000
52W return
23.0%
Low 268.0000 · High 467.8000
Lifetime High ₹485.4500 (Nov. 8, 2024)
Lifetime Low ₹2.8500 (March 12, 2009)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish6
Bearish0
5D
430.3
10D
430.0
20D
428.4
50D
415.7
100D
392.2
200D
345.8

Delivery and volume

Day avg. delivery
41.5%
Week avg. delivery
45.2%
Month avg. delivery
45.3%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

437.67
Pivot
First resistance446.33
Second resistance460.67
Third resistance469.33
First support423.33
Second support414.67
Third support400.33
Day RSI53.4
Day MFI55.9
Day MACD3.27
Day MACD signal4.36

Beta

1M0.92
3M0.06
1Y0.66
3Y0.75

Price change analysis

↑ 3.8%
Over 1 Month
LowHigh
404.10467.80
↑ 9.5%
Over 3 Months
LowHigh
362.50467.80
↑ 49.6%
Over 6 Months
LowHigh
273.15467.80
↑ 23.0%
Over 1 Year
LowHigh
268.00467.80
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 58.9 (own history: 32.3–66.7)
Sell Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹261 Cr
Net profit (June 30, 2026)
₹22 Cr
Basic EPS (June 30, 2026)
₹2.2400

Ranks #63 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter72.50%
  • Mutual funds3.43%
  • FII/FPI0.46%
  • Other DII0.25%
  • Public23.36%

Largest holders

NameCategoryShares %Shares
Jayesh Pannalal ChoksiPromoter24.6200%24690829
Zircon Teconica Private LimitedPromoter20.4700%20523330
Gufic Private LimitedPromoter10.1600%10191523
Vipula Jayesh ChoksiPromoter10.0100%10033843
Pranav Jayesh ChoksiPromoter7.2500%7268626

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 72.50% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 0.42% to 0.46% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings decreased from 3.63% to 3.43% in Jun 2026 qtr

4 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 7 insider trades, 20 SAST, 0 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
3 Jun 2022 JAYESH CHOKSI Promoter Sell 0 ₹0
3 Jun 2022 JAYESH CHOKSI Promoter Sell 0 ₹0
10 Jun 2021 Mr. Pranav J. Choksi Promoter Sell 0 ₹0
10 Jun 2021 Mr. Jayesh P.Choksi Promoter Buy 0 ₹0
10 Jun 2021 Gufic Private Limited Promoter Buy 0 ₹0
10 Jun 2021 Zircon Teconica Private Limited (Formerly known as Zircon Finance and Leasing Private Limited) Promoter Sell 0 ₹0
10 Jun 2021 Mrs. Vipula J. Choksi Immediate relative Buy 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 25 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
30 Nov 2023 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 587,787 329.7200 NSE
30 Nov 2023 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 587,787 329.6900 NSE
12 Aug 2021 FINANCIAL INVESTORS TRUST A/C GRANDEUR PEAK GLOBAL OPPORTUNITIES FUND Bulk Buy 500,000 205.8900 NSE
12 May 2021 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 460,125 189.9400 NSE
12 May 2021 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 460,125 190.0600 NSE
18 May 2017 PARTH INFIN BROKERS PVT LTD Bulk Buy 670,572 76.5400 NSE
18 May 2017 PARTH INFIN BROKERS PVT LTD Bulk Sell 670,572 76.5700 NSE
18 May 2017 GKN SECURITIES Bulk Sell 480,568 73.3100 NSE
18 May 2017 GKN SECURITIES Bulk Buy 480,568 73.9200 NSE
18 May 2017 GKN SECURITIES Bulk Buy 487,256 72.9400 BSE

All bulk and block deals →

Dividends

Full dividend history →
Last 12 months ₹0.10 per share
Dividend yield 0.02%
Ex-dateSubjectPer share (₹)Record date
— Final Dividend - Rs. - 0.1000 — —
28 Aug 2026 Dividend - Re 0.10 Per Share 0.1000 28 Aug 2026
22 Sep 2025 Dividend - Re 0.10 Per Share 0.1000 22 Sep 2025
17 Sep 2024 Annual General Meetingdividend - Re 0.10 Per Share 0.1000 —
21 Sep 2023 Annual General Meeting/Dividend - Re 0.10 Per Share 0.1000 —
24 Aug 2022 Annual General Meeting/Dividend - Rs 0.10 Per Sh 0.1000 —
9 Sep 2021 Annual General Meeting/Dividend - Rs 0.10 Per Share 0.1000 —
3 Nov 2020 Annual General Meeting/Dividend - Rs 0.05 Per Share 0.0500 —
20 Sep 2019 Annual General Meeting/Dividend - Rs 0.05 Per Equity Share 0.0500 —
19 Sep 2018 Annual General Meeting/Dividend Re 0.05 Per Share 0.0500 —

Corporate Actions

Full history (24 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
—NAME_CHANGEName changed from Central Finance Ltd. to Gufic BioSciences Ltd.
17 Sep 2009AGMAgm/Div-Re.0.05 Per Share
20 Sep 2006AGMAgm/Div-Rs.0.16/- Per Sh
22 Sep 2005AGMAgm/Div-Re 0.22/- Per Sh

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
14 Aug 2026 Financial Results Yes
29 May 2026 Financial Results/Dividend/Other business matters Yes
13 Feb 2026 Financial Results/Other business matters Yes
14 Nov 2025 Financial Results/Other business matters Yes
13 Aug 2025 Financial Results/Other business matters Yes

Corporate Announcements

All 660 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
29 Sep 2026 Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company Gufic Biosciences Limited has informed the Exchange about the intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
29 Sep 2026 Company Update Gufic Biosciences Ltd - 509079 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
28 Sep 2026 Insider Trading / SAST Gufic Biosciences Ltd - 509079 - Closure of Trading Window
28 Sep 2026 Trading Window Gufic Biosciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
28 Sep 2026 General Updates Gufic Biosciences Limited has informed the Exchange about Intimation of Environmental, Social and Governance ( ESG ) Rating
28 Sep 2026 Company Update Gufic Biosciences Ltd - 509079 - Intimation Of Environmental, Social And Governance ('ESG') Rating
24 Sep 2026 General Updates Gufic Biosciences Limited has informed the Exchange about Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
8 Sep 2026 Company Update Gufic Biosciences Ltd - 509079 - Announcement under Regulation 30 (LODR)-Credit Rating
8 Sep 2026 Credit Rating Gufic Biosciences Limited has informed the Exchange about Credit Rating
7 Sep 2026 Shareholders meeting Gufic Biosciences Limited has submitted the Exchange a copy of Scrutinizers report and voting results of 42nd Annual General Meeting held on September 04, 2026

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Healthy liquidity (Current Ratio 1.55)

Weaknesses

  • Low Return on Equity (9.7%)

Opportunities

Data unavailable.

Threats

  • PE above 35 (58.9) -- priced for continued strong execution

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Gufic Biosciences Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.